Gerald T. Proehl Acquires 29,882 Shares of Tenax Therapeutics Inc. (TENX) Stock
Tenax Therapeutics Inc. (NASDAQ:TENX) Director Gerald T. Proehl acquired 29,882 shares of the business’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was acquired at an average cost of $1.67 per share, with a total value of $49,902.94. Following the completion of the acquisition, the director now owns 15,433 shares in the company, valued at approximately $25,773.11. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Tenax Therapeutics Inc. (NASDAQ:TENX) opened at 1.93 on Thursday. The company has a 50-day moving average of $1.68 and a 200 day moving average of $2.29. Tenax Therapeutics Inc. has a 12-month low of $1.21 and a 12-month high of $3.40. The company’s market capitalization is $54.27 million.
Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Thursday, November 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.02. Equities research analysts forecast that Tenax Therapeutics Inc. will post ($0.65) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Gerald T. Proehl Acquires 29,882 Shares of Tenax Therapeutics Inc. (TENX) Stock” was originally reported by Financial Market News and is the propert of of Financial Market News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this news story can be viewed at http://www.financial-market-news.com/gerald-t-proehl-acquires-29882-shares-of-tenax-therapeutics-inc-tenx-stock/1212306/.
About Tenax Therapeutics
Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity.
Receive News & Ratings for Tenax Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.